Steven Tong profile

Steven Tong

Prof Steven Tong is an infectious diseases clinician at the Royal Melbourne Hospital (RMH) at the Doherty Institute. He leads the Staphylococcus aureus Network Adaptive Platform trial, an NHMRC funded global adaptive platform trial (GNT #1184238, CIA, 2020-2024, $4.95M; also NZ HRC, Canadian IHR grants for additional $2M) and the Australasian COVID-19 Trial (ASCOT), which has been funded through philanthropy, and has recruited >1,600 participants in Australia, NZ, India, and Nepal. He chairs: the Australasian Society for Infectious Diseases Clinical Research Network; the Translational and Clinical Research discipline at the Doherty Institute; and the Melbourne Academic Centre of Health Infection subcommittee. Prof Tong has completed clinical trials and other complex projects including CAMERA2, the largest RCT for MRSA bloodstream infections (JAMA 2020). His involvement in REMAP-CAP for COVID has further built capacity for adaptive clinical trials in infectious diseases. He has given invited talks at major international infectious diseases conferences on adaptive platform trials (ECCMID 2019, American Society Microbiology 2019). His work has also led to the discovery and naming of two new staphylococcal species and a novel genotype of Hepatitis B.

Publication | September, 2021
Publication | May, 2021
Publication | October, 2021
Antibiotic resistanceStaphylococcusMRSA
Clinical Microbiology & Infection
© 2022 Phage Australia
svelte head: undefined